Skip to main content
. 2022 May 17;10(5):e004475. doi: 10.1136/jitc-2021-004475

Table 2.

Multivariable Cox proportional hazards model for severe (grade ≥3) infection

Cox proportional-hazards model for grade ≥3 infection (D0-90) Adjusted HR (95% CI) P value
Pre-CAR-T variables
Age (≥65 yo) 1.22 (0.73 to 2.03) 0.45
Disease entity (transformed lymphoma) 1.43 (0.77 to 2.66) 0.26
Prior ASCT 0.86 (0.47 to 1.59) 0.63
ECOG performance status (≥2) 1.10 (0.74 to 1.66) 0.64
LDH >ULN 0.95 (0.54 to 1.68) 0.86
Absolute lymphocyte count (ALC) <200 /µL 0.92 (0.49 to 1.71) 0.80
IgG Levels <4 g/L 0.85 (0.49 to 1.47) 0.55
CAR-HEMATOTOX (High) 6.14 (2.93 to 12.87) <0.0001
Post-CART variables
CAR T-cell product (Tisa-cel) 1.31 (0.74 to 2.29) 0.35
ICU admission 1.22 (0.57 to 2.59) 0.61
CRS grade (ASTCT≥2°) 1.65 (0.87 to 3.16) 0.13
ICANS grade (ASTCT≥2°) 1.10 (0.50 to 2.38) 0.82
Tocilizumab use 0.93 (0.46 to 1.86) 0.83
Corticosteroid administration ≥9 days (≥10 mg Dexamethasone equivalent between D0-21) 2.08 (1.01 to 4.29) 0.047
G-CSF use 0.82 (0.44 to 1.54) 0.54
Antibacterial prophylaxis use 0.44 (0.26 to 0.77) 0.004
Severe neutropenia ≥14 days (ANC<500/µL between day 0 and 60) 3.13 (1.74 to 5.62) <0.0001

Abbreviations: ANC, Absolute Neutrophil Count; G-CSF, Granulocyte-colony stimulating factor; ASTCT, American Society for Transplantation and Cellular Therapy; ECOG, Eastern Cooperative Oncology Group; ULN, Upper Limit of Normal; ICU, Intensive Care Unit.

CAR-T, chimeric antigen receptor T-cells; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; LDH, lactate dehydrogenase.